PD-198306 | CAS#212631-61-3 | MEK1/2 Inhibitor

PD-198306
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525904

CAS#: 212631-61-3

Description: PD-198306 is a cell-permeable amino-benzamide compound that acts as a potent and non-ATP-competitive inhibitor of MEK1/2 (IC50 = 8 nM) with an excellent selectivity over ERK, c-Src, Cdk's, and PI 3-Kγ (IC50 >1.0 μM).

Chemical Structure

PD-198306

CAS# 212631-61-3

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 525904
Name: PD-198306
CAS#: 212631-61-3
Chemical Formula: C18H16F3IN2O2
Exact Mass: 476.02
Molecular Weight: 476.238
Elemental Analysis: C, 45.40; H, 3.39; F, 11.97; I, 26.65; N, 5.88; O, 6.72

Price and Availability

Size	Price	Availability
5mg	USD 410	2 Weeks
10mg	USD 700	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: PD-198306; PD 198306; PD198306.

IUPAC/Chemical Name: Benzamide, N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-((4-iodo-2-methylphenyl)amino)-

InChi Key: UHAXDAKQGVISBZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H16F3IN2O2/c1-9-6-11(22)4-5-14(9)23-17-12(7-13(19)15(20)16(17)21)18(25)24-26-8-10-2-3-10/h4-7,10,23H,2-3,8H2,1H3,(H,24,25)

SMILES Code: O=C(NOCC1CC1)C2=CC(F)=C(F)C(F)=C2NC3=CC=C(I)C=C3C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor.
In vitro activity:	TBD
In vivo activity:	Intrathecal administration of the selective MAPK/ERK-kinase (MEK) inhibitor PD 198306 dose-dependently (1-30 micro g) blocked static allodynia in both the streptozocin and the chronic constriction injury (CCI) rat models of neuropathic pain. The antihyperalgesic effects of PD 198306, in both the streptozocin and CCI models of neuropathic pain, correlated with a reduction in the elevated levels of active ERK1 and 2 in lumbar spinal cord. Reference: Br J Pharmacol. 2003 Mar;138(5):751-6. https://pubmed.ncbi.nlm.nih.gov/12642375/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	47.9	100.00
	Ethanol	47.6	100.00

Preparing Stock Solutions

The following data is based on the product molecular weight 476.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, Martel-Pelletier J. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 2003 Jun;48(6):1582-93. doi: 10.1002/art.11014. PMID: 12794826. 2. Ciruela A, Dixon AK, Bramwell S, Gonzalez MI, Pinnock RD, Lee K. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol. 2003 Mar;138(5):751-6. doi: 10.1038/sj.bjp.0705103. PMID: 12642375; PMCID: PMC1573714.
In vitro protocol:	TBD
In vivo protocol:	1. Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, Martel-Pelletier J. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 2003 Jun;48(6):1582-93. doi: 10.1002/art.11014. PMID: 12794826. 2. Ciruela A, Dixon AK, Bramwell S, Gonzalez MI, Pinnock RD, Lee K. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol. 2003 Mar;138(5):751-6. doi: 10.1038/sj.bjp.0705103. PMID: 12642375; PMCID: PMC1573714.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Franklin JM, Carrasco GA. Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling. Synapse. 2013 Mar;67(3):145-59. doi: 10.1002/syn.21626. Epub 2012 Dec 8. PubMed PMID: 23151877; PubMed Central PMCID: PMC3552103.

2: Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal. 2010 Sep;22(9):1369-78. doi: 10.1016/j.cellsig.2010.05.006. Epub 2010 May 12. PubMed PMID: 20471474; PubMed Central PMCID: PMC2893265.

3: Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, Martel-Pelletier J. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 2003 Jun;48(6):1582-93. PubMed PMID: 12794826.

4: Ciruela A, Dixon AK, Bramwell S, Gonzalez MI, Pinnock RD, Lee K. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol. 2003 Mar;138(5):751-6. PubMed PMID: 12642375; PubMed Central PMCID: PMC1573714.

Your view history

PD-198306 featured